第二个解除限售期解除限售条件成就的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 本次可解除限售的激励对象共 2 名，可解除限售的限制性股票数量为 2.64 万股，占目前公司股本总额的 0.009%。 证券代码：603309 证券简称：维力医疗 公告编号：2024-060 广州维力医疗器械股份有限公司 关于第一期限制性股票激励计划预留授予部分 本次限制性股票解除限售事宜办理完毕解除限售申请手续后，在上市流通 前，公司将另行发布公告，敬请投资者注意。 6、2021 年 12 月 1 日，公司分别召开第四届董事会第十二次会议和第四届监事 会第十一次会议，审议通过《关于调整第一期限制性股票激励计划有关事项的议案》 《关于向激励对象首次授予限制性股票的议案》，独立董事发表了独立意见。 7、2021 年 12 月 16 日，公司收到中国证券登记结算有限责任公司上海分公司 出具的《证券变更登记证明》，公司第一期限制性股票激励计划首次授予的 379.00 万股限制性股票己于 2021 年 12 月 15 日完成登 ...

广州维力医疗器械股份有限公司 监事会关于公司第一期限制性股票激励计划预留授予部分 第二个解除限售期解除限售条件成就的核查意见 广州维力医疗器械股份有限公司〈以下简称"公司"）监事会根据《公司 法》《证券法》《上市公司股权激励管理办法》和《公司章程》的有关规定,就 公司第一期限制性股票激励计划预留授予部分第二个解除限售期解除限售条件 成就发表核查意见如下: 公司第一期限制性股票激励计划预留授予部分第二个解除限售期解除限售 条件已经成就,本次可解除限售的2名激励对象的主体资格合法、有效,符合 公司《第一期限制性股票激励计划(草案)》规定的解除限售条件,审议程序合 法、合规,不存在损害公司及股东利益的情形。我们同意公司按照本激励计划 相关规定对符合解除限售条件的 2 名激励对象持有的 2. 64 万股限制性股票办理 解除限售相关事宜。 （此页无正文，为《广州维力医疗器械股份有限公司监事会关于公司第一期限制 性股票激励计划预留授予部分第二个解除限售期解除限售条件成就的核查意见》 之签字页) 1.17 赵彤威 舒 杰 蔡国柱 1 万座井器械股份有限公司 广州省 监事会 监事签名: ...

深圳市他山企业管理咨询有限公司 关于广州维力医疗器械股份有限公司 第一期限制性股票激励计划预留授予部分 第二个解除限售期解除限售条件成就的 独立财务顾问报告 二〇二四年十一月 | 释 义 | 2 | | --- | --- | | 声 明 | 3 | | 一、本激励计划已履行的审批程序 | 4 | | 二、关于预留授予部分第二个解除限售期解除限售条件成就的说明 | 8 | | 三、本次解除限售情况 | 11 | | 四、独立财务顾问意见 | 12 | | 五、备查文件及备查地点 | 13 | | （一）备查文件 | 13 | | （二）备查地点 | 13 | 深圳市他山企业管理咨询有限公司 独立财务顾问报告 释 义 在本报告中，除非上下文文意另有所指，下列词语具有如下含义： | 维力医疗、公司 | 指 | 广州维力医疗器械股份有限公司（证券简称：维力医 | | --- | --- | --- | | | | 疗；证券代码：603309） | | 股权激励计划、限制性股票 | 指 | 广州维力医疗器械股份有限公司第一期限制性股票 | | 激励计划、本激励计划 | | 激励计划 | | 《股权激励计划（草案）》、 ...

Group 1: Financial Performance - In the first three quarters of 2024, the company achieved operating revenue of 106,042.91 million yuan, a year-on-year increase of 8.53% [1] - The net profit attributable to shareholders of the parent company reached 16,672.64 million yuan, growing by 15.85% [1] - The third quarter of 2024 saw operating revenue of 38,417.83 million yuan, up 18.16% year-on-year, with a net profit of 6,067.28 million yuan, increasing by 17.04% [1] - The net profit after deducting non-recurring gains and losses was 5,898.46 million yuan, reflecting a year-on-year growth of 21.18% [1] Group 2: Market Expansion and Strategy - The company is constructing a factory in Mexico to meet the growing capacity demands of overseas clients and to enhance its global layout strategy [2] - The Mexican factory will be built in two phases, with the first phase focusing on automated production lines for North and South American clients, expected to be operational by early 2026 [2] - The establishment of the factory is anticipated to significantly improve the company's overseas product supply and customer service capabilities, enhancing its competitiveness and risk resilience [2] Group 3: Customer and Market Response - Overseas clients have shown strong support for the company's factory in Mexico, viewing it as beneficial for reducing transportation and storage costs while improving procurement and communication efficiency [2] - The company has implemented robust foreign exchange management practices, minimizing the impact of currency fluctuations on overall performance [2] Group 4: Future Development Strategy - The company will continue to focus on the medical catheter field while expanding into active medical devices through independent and collaborative R&D [3] - Recent acquisitions have enriched the product matrix in anesthesia and urology, aiming to enhance revenue through product synergy [3] - The strategic goal is to become a global leader in the research and manufacturing of medical catheters and related products [3]

Summary of Conference Call Records Company and Industry Overview - The conference call discusses the performance and outlook of a medical device company, focusing on both domestic and international sales trends, particularly in the context of regulatory changes and market dynamics [1][2][21]. Key Points and Arguments Sales Performance - The company reported nearly 30% growth in overseas revenue for the first three quarters, with expectations of maintaining a growth rate between 25% to 30% for the fourth quarter [1][2]. - Domestic sales were initially below expectations, with a decline of 14% in the first half of the year, but showed signs of recovery with a projected decline of only 8% by September [5][21]. - The overall sales outlook for the company remains positive, with expectations of a stable growth trend in overseas sales and potential recovery in domestic sales [3][21]. Market Dynamics - Concerns regarding U.S. tariffs were addressed, indicating that the company’s orders from the U.S. account for about 25% of total overseas sales, and that potential tariff increases may not significantly impact overall order flow [2][21]. - The company noted that competition remains strong domestically, and any tariff-related challenges could potentially benefit the company by attracting orders from smaller competitors [2][3]. Product and Innovation - The company is focusing on high-margin new products, which are expected to grow at a faster rate than overall sales, with some new products already achieving sales levels 2.3 times higher than the previous year [4][21]. - New product launches are anticipated to contribute significantly to revenue, with expectations of new clients and products entering the market in the coming year [12][21]. Production Capacity and Expansion - The company is expanding its production capacity, with a new facility in Mexico expected to be operational within 12 to 15 months, and a facility in Zhaoqing projected to begin production in the second half of next year [13][14]. - The planned production capacity in Mexico is estimated at around 1.5 billion RMB annually, while the Zhaoqing facility could reach 8 to 10 billion RMB if fully operational [13][14]. Regulatory and Market Challenges - The company faces challenges with the slow progress of centralized procurement (集采), which has not met initial expectations, impacting domestic sales growth [8][21]. - The introduction of new products, particularly in the Guangdong region, is seen as a positive development, although other regions have not yet shown similar improvements [9][21]. Future Outlook - The company anticipates a stable performance for the remainder of the year, with overseas sales expected to grow by over 20% next year, while domestic sales could also see a growth rate of 15% to 30% depending on policy changes [21][22]. - The overall sentiment is optimistic, with expectations of continued growth driven by new product introductions, market expansion, and improved operational efficiencies [22]. Additional Important Insights - The company is actively working on enhancing automation in its production processes, with the goal of reducing costs and improving efficiency [16][17]. - There is a strong emphasis on the potential of new treatment devices, particularly in the male health sector, which could capture significant market share given the limited competition [18][20]. This summary encapsulates the key insights from the conference call, highlighting the company's performance, market dynamics, product innovation, and future outlook.

Summary of the Conference Call for Guangzhou Weili Medical Infrastructure Co., Ltd. Q3 2024 Performance Company Overview - **Company Name**: Guangzhou Weili Medical Infrastructure Co., Ltd. - **Industry**: Medical Equipment - **Main Business Lines**: Anesthesia, Urinary, Surgical Materials, Nursing, Respiratory, Hemodialysis with over 100 products [1][2] Core Points and Arguments - **Revenue Growth**: - For the first nine months of 2024, the company achieved a revenue of 1.03 billion yuan, representing an 8% year-on-year increase [3] - Export revenue reached 560 million yuan, showing a significant growth of 28% year-on-year, while domestic sales decreased by approximately 8.7% to 470 million yuan [4] - **Profit Performance**: - The net profit attributable to the parent company was 167 million yuan, reflecting a 15.85% increase year-on-year, with a net profit after deductions of 160 million yuan, up 21.18% [3][5] - The profit growth rate outpaced revenue growth, attributed to improved internal pricing efficiency and a decrease in average product costs [5] - **Market Dynamics**: - The company has maintained a balanced development strategy between domestic and international sales, contributing to long-term stable growth [2] - The domestic market is gradually recovering, with Q3 showing a positive trend, achieving 140 million yuan in revenue, a 5% increase [5][6] - **Product Development and Innovation**: - The company emphasizes quality management and continuous innovation, having been recognized as a Class A medical device manufacturer in Guangdong Province for 16 consecutive years [2] - Ongoing investment in R&D to meet changing customer demands and enhance product design [2] Additional Important Information - **Challenges**: The company faces challenges from global political and economic conditions, which have been described as severe [2] - **Future Outlook**: The company aims to accelerate domestic market promotion and overseas localization efforts to ensure sustainable growth and deliver better results for investors [3] This summary encapsulates the key points discussed during the conference call, highlighting the company's performance, market strategies, and future outlook in the medical equipment industry.

证券代码：603309 证券简称：维力医疗 公告编号：2024-058 广州维力医疗器械股份有限公司 关于公司产品获得加拿大卫生部认证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 广州维力医疗器械股份有限公司（以下简称"公司"）于近日收到一项加拿大 卫生部颁发的 2 类医疗器械产品注册证，公司产品输尿管扩张器获得了加拿大卫生 部认证。现将有关情况公告如下： 一、医疗器械注册证的具体情况 产品名称：Ureteral Dilator（输尿管扩张器） 产品规格：Ureteral Dilator Set（输尿管扩张器套件），6-18Fr 证书编号：112100 持证方：广州维力医疗器械股份有限公司 持证方住所：广东省广州市番禺区化龙镇金湖工业城 C 区 4 号 注册分类：2 类产品证书 发证机构：Health Canada 加拿大卫生部 获证时间：2024 年 10 月 30 日 公司产品输尿管扩张器获得加拿大卫生部认证，表明其可以在加拿大市场合法 销售，对产品在海外市场的推广和销售起到积极推动作用。 三、风险提示 公 ...

Investment Rating - The report maintains a "Recommended" investment rating for the company with a target price of 19 yuan, compared to the current price of 13.74 yuan [1]. Core Insights - The company's revenue for the first three quarters of 2024 reached 1.06 billion yuan, reflecting an increase of 8.53% year-on-year, while the net profit attributable to shareholders was 167 million yuan, up 15.85% [1]. - In Q3 2024, the company achieved a revenue of 384 million yuan, representing an 18.16% increase year-on-year, and a net profit of 61 million yuan, which is a 17.04% increase [1]. - Domestic business is gradually recovering, and overseas revenue is experiencing high growth, with domestic sales increasing by 5.35% and overseas sales growing by 28.73% [1]. - The company is actively building new production capacity to meet the increasing demand from domestic medical supply procurement and overseas clients, including a fully automated production base in Zhaoqing and a factory in Mexico [1]. Financial Summary - The company forecasts net profits of 240 million yuan, 300 million yuan, and 380 million yuan for 2024, 2025, and 2026, respectively, with year-on-year growth rates of 23.1%, 26.1%, and 26.2% [2][5]. - The earnings per share (EPS) are projected to be 0.81 yuan, 1.02 yuan, and 1.29 yuan for the same years, with corresponding price-to-earnings (PE) ratios of 17, 13, and 11 [2][5]. - The comprehensive gross margin for Q3 2024 was 44.32%, remaining stable year-on-year, while the net profit margin reached 16.03% [1].

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company has shown steady growth in both domestic and international sales, with innovative products rapidly gaining market traction [2] - The operational efficiency has improved, leading to a reduction in expense ratios, which has positively impacted the net profit margin [2] - The company is expected to achieve significant revenue and profit growth in the coming years, supported by strong overseas market performance and product innovation [2] Summary by Relevant Sections Financial Performance - For the third quarter of 2024, the company reported revenue of 1.06 billion, a year-on-year increase of 8.53%, and a net profit of 167 million, up 15.85% [1] - The company achieved a net profit margin of 16.24%, an increase of 0.69 percentage points year-on-year [2] Revenue and Profit Forecast - Projected revenues for 2024, 2025, and 2026 are 1.637 billion, 1.971 billion, and 2.338 billion respectively, representing year-on-year growth rates of 17.96%, 20.40%, and 18.63% [2] - Expected net profits for the same years are 240 million, 290 million, and 348 million, with growth rates of 24.66%, 20.85%, and 20.08% respectively [2] Market and Product Development - The company has successfully launched innovative products in overseas markets, resulting in a 28.73% increase in export revenue [2] - Domestic sales have also seen a growth of 5.35%, aided by the gradual recovery of new product admissions in certain provinces [2] Operational Efficiency - The company has reduced its sales and management expense ratios, leading to a decrease in overall expense ratios by 1.10 percentage points [2] - The establishment of automated production lines in both domestic and overseas facilities is expected to further enhance profit margins [2]

证券代码：603309 证券简称：维力医疗 公告编号：2024-057 广州维力医疗器械股份有限公司 截至本公告披露日，公司 2021 年非公开发行股票募集资金专项账户情况如 下： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 | 开户单位名称 | 开户银行 | 银行账号 | 募集资金使用项 | 账户 | | --- | --- | --- | --- | --- | | | | | 目名称 | 状态 | | 广 州 维 力 医 疗 器 械 股 份 有 限 | 上海浦东发展银行 股份有限公司广州 | 82140078801200002497 | 营销中心建设项 | 存续 | | | | | 目 | | | 公司 | 珠江新城支行 | | | | | 广 州 维 力 医 疗 器 械 股 份 有 限 | 中国银行股份有限 | 654875235602 | 一次性使用合金 涂层抗感染导尿 | 存续 | | | 公司广州番禺支行 | | | | | 公司 | | | 管生产建设项目 | | | 广 州 维 力 医 疗 器 械 ...